Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ecto-NOX disulfide-thiol exchanger 2 (ENOX2), commonly referred to as tumor-associated NADH oxidase (tNOX), is a cancer-specific cell surface glycoprotein that plays a pivotal role in regulating cell growth, proliferation, and survival. It exhibits two alternating enzymatic activities: the oxidation of NADH (or hydroquinones) and protein disulfide-thiol interchange, which generate intrinsic oscillations that act as an ultradian cellular clock linked to cell enlargement. ENOX2 is produced via cancer-specific alternative splicing and is highly expressed on the outer leaflet of the plasma membrane of various cancer cells, while being virtually absent or inactive on normal, non-transformed cells. This tumor-specific expression makes it an attractive therapeutic target and a valuable biomarker for early cancer detection through liquid biopsies.
Inhibition of ENOX2 by small molecules, such as phenoxodiol (idronoxil), ME-143, capsaicin, and epigallocatechin gallate (EGCG), blocks its enzymatic activities, leading to an accumulation of cytosolic NADH and a disruption of the intracellular NAD+/NADH ratio. This redox imbalance suppresses the activity of the NAD+-dependent deacetylase sirtuin 1 (SIRT1), thereby enhancing the acetylation of key proteins like p53 and c-Myc, which triggers cell cycle arrest and apoptosis. Additionally, ENOX2 inhibition alters sphingolipid metabolism by reducing prosurvival sphingosine-1-phosphate and elevating proapoptotic ceramide levels, further driving programmed cell death. Because of its localization on the external cell surface, drugs targeting ENOX2 do not need to enter the cell to exert their anticancer effects, offering a unique therapeutic advantage with minimized systemic toxicity.
Inhibition of NADH oxidase and protein disulfide-thiol interchange activities, leading to accumulation of cytosolic NADH, disruption of the NAD+/NADH ratio, inhibition of SIRT1 deacetylase activity, and induction of apoptosis via sphingolipid pathway modulation (elevating ceramide and reducing sphingosine-1-phosphate).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ecto-NOX disulfide-thiol exchanger 2 (ENOX2).